{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:16:58Z","timestamp":1788959818873,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Haemophilia B patients with factor IX inhibitors have particularly unmet needs for conventional therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Phase II\/III clinical trial, multicentre, open\u2010label, prospective, self\u2010controlled study was conducted to assess MC710 prophylaxis in haemophilia B patients with inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled haemophilia patients who had received episodic or prophylactic treatment with bypassing agents up to that time. The participants continued their conventional therapy for 24\u00a0weeks and then MC710 was prophylactically infused intravenously every 2 or 3 days at 60 to 120\u00a0\u03bcg as FVIIa per kilogram of body weight for 24\u00a0weeks. The primary endpoint was the annual bleeding rate (ABR) requiring bypassing agents, which was compared intraindividually between the conventional therapy period and the MC710 prophylaxis period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 11 male haemophilia B patients were enrolled. The median ABR ratio for each participant (the prophylaxis period ABR divided by the conventional therapy period ABR) was .33 (2.1\/6.5), range from .00 to 3.77. ABR ratios for 9 of the 11 patients ranged from .00 to .60, and 3 of the 9 patients had zero bleeding events during the prophylaxis period. Meanwhile, ABR ratios for the remaining two patients were 2.53 and 3.77, respectively. Although a fibrinogen decrease recovered by the dose reduction was reported for only one participant as the sole adverse drug reaction in this study, no thrombotic events or other safety concerns were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MC710 prophylaxis is considered to be decrease the bleeding rate in haemophilia B patients with inhibitors without safety concerns.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14710","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T19:46:06Z","timestamp":1671047166000},"page":"456-465","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Plasma\u2010derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors"],"prefix":"10.1111","volume":"29","author":[{"given":"Michio","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Pediatrics Munakata Suikokai General Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Tokyo Medical University Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nihon University Itabashi Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Takedani","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery IMSUT Hospital The Institute of Medical Science The University of Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Kyoto City Hospital  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sakashita","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Nagano Children's Hospital  Nagano Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Taki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics St. Marianna University Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Japanese Red Cross Kumamoto Hospital  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Tokushima University Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Kyushu University Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Harano","sequence":"additional","affiliation":[{"name":"Department of Clinical Development KM Biologics Co., Ltd.  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shirahata","sequence":"additional","affiliation":[{"name":"Kitakyushu Yahata Higashi Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"issue":"5","key":"e_1_2_11_3_1","first-page":"s116","article-title":"Advances in hemophilia and the role of current and emerging prophylaxis","volume":"22","author":"Acharya SS","year":"2016","journal-title":"Am J Manag Care"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00006.x"},{"issue":"2","key":"e_1_2_11_6_1","first-page":"3","article-title":"ITI in hemophilia B: possibilities and problems","volume":"8","author":"Warrier I","year":"2000","journal-title":"International Monitor of Haemophilia"},{"key":"e_1_2_11_7_1","unstructured":"World Federation of Hemophilia Annual Global Survey 2020. Accessed April 8 2022.https:\/\/www1.wfh.org\/publications\/files\/pdf\u20102045.pdf"},{"key":"e_1_2_11_8_1","first-page":"51","article-title":"Anamnestic response following infusion of prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (APCC) in haemophilia A patients with inhibitors","volume":"2","author":"Yoshioka A","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.12.010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02548.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12205"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13050"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14710","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:56:31Z","timestamp":1699012591000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/hae.14710"],"URL":"https:\/\/doi.org\/10.1111\/hae.14710","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"2022-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}